A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. The intratumoral administration of these repurposed vaccines can induce immune cell infiltration into the treated tumor. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR)...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Molecular Therapy: Oncolytics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770522000547 |
| _version_ | 1818140047247933440 |
|---|---|
| author | Manlio Fusciello Erkko Ylösmäki Sara Feola Arttu Uoti Beatriz Martins Karri Aalto Firas Hamdan Jacopo Chiaro Salvatore Russo Tapani Viitala Vincenzo Cerullo |
| author_facet | Manlio Fusciello Erkko Ylösmäki Sara Feola Arttu Uoti Beatriz Martins Karri Aalto Firas Hamdan Jacopo Chiaro Salvatore Russo Tapani Viitala Vincenzo Cerullo |
| author_sort | Manlio Fusciello |
| collection | DOAJ |
| description | Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. The intratumoral administration of these repurposed vaccines can induce immune cell infiltration into the treated tumor. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR) vaccine in our previously developed PeptiENV cancer vaccine platform. The intratumoral administration of this novel MMR-containing PeptiENV cancer vaccine significantly increased both intratumoral as well as systemic tumor-specific T cell responses. In addition, PeptiENV therapy, in combination with immune checkpoint inhibitor therapy, improved tumor growth control and survival as well as increased the number of mice responsive to immune checkpoint inhibitor therapy. Importantly, mice pre-vaccinated with the MMR vaccine responded equally well, if not better, to the PeptiENV therapy, indicating that pre-existing immunity against the MMR vaccine viruses does not compromise the use of this novel cancer vaccine platform. |
| first_indexed | 2024-12-11T10:37:46Z |
| format | Article |
| id | doaj.art-38eb34c95a1041b2ad52990b03671885 |
| institution | Directory Open Access Journal |
| issn | 2372-7705 |
| language | English |
| last_indexed | 2024-12-11T10:37:46Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncolytics |
| spelling | doaj.art-38eb34c95a1041b2ad52990b036718852022-12-22T01:10:40ZengElsevierMolecular Therapy: Oncolytics2372-77052022-06-0125137145A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubellaManlio Fusciello0Erkko Ylösmäki1Sara Feola2Arttu Uoti3Beatriz Martins4Karri Aalto5Firas Hamdan6Jacopo Chiaro7Salvatore Russo8Tapani Viitala9Vincenzo Cerullo10Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; Corresponding author Erkko Ylösmäki, Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandPharmaceutical Biophysics Research Group, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, FinlandDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandPharmaceutical Biophysics Research Group, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, FinlandDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; Department of Molecular Medicine and Medical Biotechnology, Naples University “Federico II”, S. Pansini 5, Naples, Italy; Corresponding author. Vincenzo Cerullo, Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. The intratumoral administration of these repurposed vaccines can induce immune cell infiltration into the treated tumor. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR) vaccine in our previously developed PeptiENV cancer vaccine platform. The intratumoral administration of this novel MMR-containing PeptiENV cancer vaccine significantly increased both intratumoral as well as systemic tumor-specific T cell responses. In addition, PeptiENV therapy, in combination with immune checkpoint inhibitor therapy, improved tumor growth control and survival as well as increased the number of mice responsive to immune checkpoint inhibitor therapy. Importantly, mice pre-vaccinated with the MMR vaccine responded equally well, if not better, to the PeptiENV therapy, indicating that pre-existing immunity against the MMR vaccine viruses does not compromise the use of this novel cancer vaccine platform.http://www.sciencedirect.com/science/article/pii/S2372770522000547oncolytic virusescancer vaccinesPriorixmumpsmeaslesrubella |
| spellingShingle | Manlio Fusciello Erkko Ylösmäki Sara Feola Arttu Uoti Beatriz Martins Karri Aalto Firas Hamdan Jacopo Chiaro Salvatore Russo Tapani Viitala Vincenzo Cerullo A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella Molecular Therapy: Oncolytics oncolytic viruses cancer vaccines Priorix mumps measles rubella |
| title | A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella |
| title_full | A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella |
| title_fullStr | A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella |
| title_full_unstemmed | A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella |
| title_short | A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella |
| title_sort | novel cancer vaccine for melanoma based on an approved vaccine against measles mumps and rubella |
| topic | oncolytic viruses cancer vaccines Priorix mumps measles rubella |
| url | http://www.sciencedirect.com/science/article/pii/S2372770522000547 |
| work_keys_str_mv | AT manliofusciello anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT erkkoylosmaki anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT sarafeola anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT arttuuoti anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT beatrizmartins anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT karriaalto anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT firashamdan anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT jacopochiaro anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT salvatorerusso anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT tapaniviitala anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT vincenzocerullo anovelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT manliofusciello novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT erkkoylosmaki novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT sarafeola novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT arttuuoti novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT beatrizmartins novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT karriaalto novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT firashamdan novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT jacopochiaro novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT salvatorerusso novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT tapaniviitala novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella AT vincenzocerullo novelcancervaccineformelanomabasedonanapprovedvaccineagainstmeaslesmumpsandrubella |